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OVERVIEW — Despite the vital role they play in public health, childhood
vaccines travel a complicated road from laboratory to provider and patient.
From the fall of 2000 until well into 2002, a combination of factors, including
market dynamics, legal challenges, and regulatory hurdles, led to a shortage of
some childhood vaccines. This paper examines each of these factors, focusing
on the important roles of both the public and the private sectors.
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U.S. Childhood Vaccine
Availability: Legal, Regulatory,
and Economic Complexities
Vaccines have been heralded as one of the most cost-effective public
health and biomedical success stories. Protecting against once-dreaded
diseases ranging from polio to diphtheria, they are a staple of most U.S.
children’s routine medical care.1  In the past two years, however, “unique
and unprecedented” shortages of vaccines for children2  have left health
professionals frustrated and legislative leaders demanding explanations.
And the post–September 11 environment, in which the specter of poten-
tial bioterror agents such as anthrax and smallpox looms large, has ex-
panded concerns over the nation’s vaccine infrastructure from the largely
pediatric arena to the realm of homeland security.
Eleven childhood diseases are currently vaccine-preventable. As of June
2002, five vaccines that provide protection against eight of these dis-
eases—diphtheria, tetanus, pertussis (DTaP and Td vaccine), pneumo-
coccal infection (PCV-7 vaccine), measles, mumps, rubella (MMR vac-
cine), and varicella—were in short supply.3  Although, with the excep-
tion of PCV-7, these vaccines are again widely available,4  the research
obstacles, development and manufacturing complexities, regulatory and
legislative challenges, and production and distribution difficulties that
led to the shortages are all potential harbingers of 21st century public
health and medical challenges.
With commercial pharmaceutical and biotechnology companies, health
plans, and providers integral partners in vaccine policy and delivery, the
private sector as well as the federal and state governments are critical to
ensuring that vaccines are available and safe. The recent and ongoing
efforts to meet childhood immunization goals can provide critical insights
for policymakers and public health officials monitoring the dual threats
of bioterrorism and naturally emerging and reemerging infectious dis-
eases that may be prevented by vaccines.
PUBLIC HEALTH IMPLICATIONS AND TENSIONS
The public health implications of childhood immunization and vaccine
policy are considerable. They reach far beyond individual children and
families into society as a whole and contribute to tensions between the
public and the private sectors over the research, development, and manu-
facture of vaccines. These tensions are over and above those surround-
ing prescription drugs, because of the different role that vaccines play
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in public health. For example, unlike prescription drugs, vaccines are
administered to healthy people, most often infants and children. Also
unlike prescription drugs, they are (with some exceptions) compulsory—
children cannot enter or attend school or day care in most states with-
out documentation showing receipt of the minimum vaccine dose re-
quired by the state.
Despite vaccines’ wide acceptance and use after the initial controversy that
surrounded them,5  over the last several years there has been evidence of a
shift in public attitudes concerning their use in children. This rising con-
cern has been fueled in part by fears about vaccine safety as well as by
religious objections and resentment of government-mandated vaccine policy
by “parents’ rights” advocates. Nevertheless, most recognize that, as the
public health community often notes, dangerous infectious diseases that
are largely under control in this country are “only a plane ride away” and
that, consequently, immunization is important to everyone.
Immunizing a child not only protects him or her, but also helps to pro-
tect the community at large, particularly those with chronic diseases
and suppressed immune systems. Immunization can also reduce disease
outbreaks. Ironically, many health officials are concerned that the very
success of vaccine programs actually may contribute to their downfall.
For example, most parents have never seen an active case of measles,
whooping cough, polio, or lockjaw (an effect of tetanus infection). Some
who do not want their own children exposed to the potential risks asso-
ciated with vaccines argue that, since the majority of other children have
been inoculated, chances of a disease outbreak are slim.
The dangers inherent in relying on community immunity—or “herd im-
munity,” as it is sometimes called—are numerous. Children run the risk
of contracting a communicable disease while traveling outside the coun-
try. Even if they do not leave the United States, they may be exposed to
an unimmunized person carrying disease: immunization levels among
U.S. residents are not 100 percent, and the United States is visited by
nearly 1 million people each day whose immunization status is not checked
and who may therefore carry vaccine-preventable disease. Experience
has shown that, when the childhood immunization rate, or “coverage
level,” drops, epidemics ensue, and at that point it may be too late to
protect the youngest and most vulnerable children. A recent paper put
out by the PATH (Program for Appropriate Technology in Health)
Children’s Vaccine Program underscored this point:
Many people in North America and Europe have become complacent
about vaccines, assuming that since certain diseases rarely appear, they
are no longer a threat. Others fear that the vaccine itself is more danger-
ous than the disease. These misperceptions have caused
underimmunization rates that have led to a resurgence of highly conta-
gious diseases such as measles, diphtheria, and pertussis. A measles
outbreak in the United States in 1989 led to 123 deaths—ninety percent
of those who died had not been vaccinated.6
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In the United States, outstanding progress has been made in immuniz-
ing children by the time they are two years of age. According to Walter
A. Orenstein, M.D., director of the National Immunization Program of
the Centers for Disease Control and Prevention:
Coverage for most vaccines is 90 percent or higher....[E]very day in the
U.S., 11,000 babies are born who must be vaccinated. To be protected
against 11 vaccine-preventable diseases, they require 16-20 doses or
injections by 2 years of age, a challenge for any health care delivery
system. Recent small, but significant, decreases in coverage for some
vaccines indicate we cannot take for granted that past successes will
automatically translate into future successes.7
Recent shortages have made it particularly difficult for physicians and
other health providers to keep track of who has been vaccinated and who
requires follow-up. They have also placed added burdens on parents to
ensure that their children are adequately immunized.
The shortages have also exacerbated the tensions that exist between the
public and the private sectors over vaccines. While the government plays
an early role in vaccine research, through the National Institutes of Health
(NIH) and other agencies, most of the research, development, and manu-
facturing takes place in the private sector. On the one hand, while vac-
cines represent an individual medical intervention, they are also consid-
ered by most to be a social good. Therefore, it has been argued, society
has an obligation to make vaccines available at the lowest possible price
to ensure widespread access. But the vaccine development system is
grounded principally in the private sector, which must earn a profit in
order to satisfy Wall Street and shareholders. Vaccine companies share
society’s goals but also must balance them with the commercial viability,
product liability, and market potential of the products they research, de-
velop, and manufacture.
It is unlikely that these tensions can ever be completely resolved, but vac-
cine shortages undermine the nation’s ability to protect the health of its
citizens in the face of threats such as bioterrorism, and both the public
and the private sectors have critical roles to play in ensuring that vac-
cines are available when needed. In an Institute of Medicine (IOM) report
entitled Setting the Course: A Strategic Vision for Immunization—Part 2, Ber-
nard Guyer, M.D., highlighted the connection between childhood vac-
cine shortages and public health in times of crisis:
The quality of the immunization system can be seen as an indicator of the
strength of the public health infrastructure. If the nation cannot ensure
that the 11,000 children born each day receive the routine immunizations
that they need, it may not be able to adequately protect the health of all
280 million Americans in times of crisis. Although crisis can stimulate
action, sustained efforts are necessary to maintain the public health infra-
structure and achieve immunization goals.8
Vaccine shortages un-
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VACCINES: WHAT THEY ARE AND
HOW THEY WORK
The last century has witnessed the spectacular reduction of horrific dis-
eases. Many can remember (or recall seeing pictures of) children in iron
lungs, the result of succumbing to paralytic polio. With the launch of the
universal Salk vaccination effort in April 1955, millions of people were
spared. While, only 50 years ago, polio was the leading cause of paralysis
in the world, the polio vaccine has raised the expectation that the world
will soon be free from the disease.9  Similarly, naturally occurring small-
pox was eradicated in 1980 through global vaccination. Other success sto-
ries abound.10
Vaccines are administered via injection, oral administration, or through
inhalation by aerosol and powder and can be either a “live” weakened
(attenuated) or dead (inactivated) disease germ. Vaccines create immu-
nity—protection against a disease. The primary purpose of the immune
system is to identify foreign substances often referred to as antigens. In
response to a vaccine, the body produces antibodies (protein molecules)
or immune system cells (producing what is known as cell-mediated im-
munity). These responses assist with the elimination of the antigens and
remain in the body, safeguarding the vaccinated person from future
disease germs.
GETTING SAFE VACCINES TO CHILDREN:
SOME FEDERAL ROLES
The federal government has an expansive commitment to vaccines. More
than 20 different agencies have a role in vaccine research.11  A number of
agencies and programs within the Department of Health and Human
Services (DHHS) play a role in national, state and local immunization
efforts. The National Vaccine Program Office within the Office of the As-
sistant Secretary for Health, for example, has the responsibility to coordi-
nate all federal, state, provider, industry, and other stakeholder efforts
around vaccines. In addition to its involvement in research and coordina-
tion, the federal government plays an integral role in (a) licensing and
regulating vaccines to ensure that they are safe and (b) financing and pur-
chasing childhood vaccines. This section focuses on these last two areas
of federal involvement.
Regulation and Licensure of Vaccine Products
Vaccines are biologic agents, that is, complex products derived from
living sources. Unlike the structure of most drugs, which are chemically
synthesized, that of biologics is not well characterized. Biologic prod-
ucts such as vaccines are subject to licensure (approval for marketing)
under provisions of the Public Health Service Act. The Food and Drug
Administration (FDA) has the responsibility to regulate vaccines in the
United States.
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Vaccine clinical development follows the same general pathway as that
for drugs. Vaccine licensure is a lengthy process that may take ten years
or more. Before a vaccine is licensed by the FDA, it is extensively tested
in the laboratory, in animals, and in human beings to ensure its safety.
Prelicensure clinical trials are done in three phases: Phase 1 (safety and
immunogenicity studies), Phase 2 (dose-ranging studies), and Phase 3
(effectiveness and additional large-scale safety studies). If successful,
the completion of all three phases of clinical development can be fol-
lowed by the submission of a biologics license application, or BLA. Dur-
ing this stage the manufacturing facility undergoes a pre-approval in-
spection during which vaccine production is examined in detail. Vaccine
licensing also requires the provision and FDA approval of adequate la-
beling information.
Once a vaccine is approved and licensed, the FDA continues to oversee its
production to ensure continuing safety. This oversight involves periodic
facility inspections. In addition, as part of the manufacturing process, both
the manufacturer and the FDA are required to perform certain tests twice
on each lot of the product before it is released for distribution.12
As part of the post-licensure monitoring, the federal government’s pas-
sive surveillance system, VAERS (the Vaccine Adverse Event Reporting
System), is designed to capture information on rare side-effects and de-
layed reactions that may not be evident until the vaccine is administered
to millions of people.13  Another post-marketing surveillance system es-
tablished by the federal government is the Vaccine Safety Datalink Project
(VSD), a collaborative project involving the Centers for Disease Control
and Prevention (CDC) and several large managed-care organizations. A
“large-linked” database, the VSD contains medical and immunization
information on more than 7 million people. In addition to these systems,
individual vaccine companies invest significant resources in developing
their own surveillance systems. Merck, for example, has used its own
funding to set up quality-control reporting systems, in addition to the
government systems already in place. Other vaccine manufacturers have
implemented similar programs.
Vaccine Safety Issues and Responses — Among the goals of the federal
government in the regulation of vaccines, ensuring that they are safe is
paramount. It is expected that the safety of a product administered to
healthy children and adults will be continuously scrutinized and ques-
tioned. Both Congress and the FDA have responded vigorously to con-
cerns about vaccine safety to maintain public confidence and thereby
ensure the health of the public.
Although vaccines are among the safest of all medical interventions, in
the mid-1980s, the number of lawsuits related to potential vaccine inju-
ries began to rise. As litigation costs soared, prices escalated and several
vaccine manufacturers halted production. The number of vaccine manu-
facturers plummeted and shortages occurred. Public health officials were
concerned about the potential return of disease epidemics. In response
Both Congress and the
FDA have responded
vigorously to concerns
about vaccine safety.
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to the situation, Congress passed the National Childhood Vaccine In-
jury Act (NCVIA) of 1986. Key among the many provisions of the NCVIA
were the establishment within DHHS of the National Vaccine Program
Office, the creation of the National Vaccine Injury Compensation Pro-
gram within the Health Resources and Services Administration (to com-
pensate those injured by vaccines on a “no fault” basis), and the require-
ment that all health care providers report certain adverse events fol-
lowing inoculation to the secretary of health and human services.
Since the mid-1990s, accusations about the safety of vaccines have pro-
liferated in some circles, largely through the use of the Internet. In-
creased attention to vaccine safety issues, coupled with the widespread
use of childhood vaccines, resulted in a request by the CDC and the
NIH to have the Institute of Medicine “convene an independent com-
mittee that could provide timely and objective assistance to the Depart-
ment of Health and Human Services in reviewing emerging immuniza-
tion-safety hypotheses.”14  The first report specifically reviewed the al-
leged relationship between the measles, mumps, rubella vaccine and
autistic spectrum disorders (ASDs). At the end of their analyses, the
IOM committee members concluded:
although…the evidence favors rejection of the causal relationship at
the population level between MMR vaccine and autistic spectrum dis-
orders, the committee nevertheless recommends that this issue receive
continued attention. It does so in the recognition that its conclusion
does not exclude the possibility that MMR vaccine could contribute to
ASD in a small number of children, as well as the following factors: the
identified limitations of the evidence, the burden of ASD, the burden of
the diseases prevented by the vaccine, the immense concern of parents,
and the prominence of the issue in public debate.15
Another prominent issue regarding vaccine safety in recent years has
been the use of preservatives, particularly thimerosal, a mercury-contain-
ing organic compound (an organomercurial). Since the 1930s, thimerosal
has been used as a preservative in many biological and drug products,
including vaccines, to prevent potentially life-threatening contamination
from microbes such as staphylococci. Because of the “theoretical potential
for neurotoxicity of even low levels of organomercurials and because of
the increased number of thimerosal containing vaccines that have been
added to the infant immunization schedule,”16  concerns about its use have
been brought center stage. As a result, the FDA has worked with vaccine
manufacturers to reduce or eliminate thimerosal from most vaccines.17
In addition to regulating the manufacture of vaccines, the U.S. govern-
ment has a strong interest in efforts being made by other governments
and by vaccine companies to improve the safety of vaccine delivery
systems. Among the technologies that hold the promise of increasing
vaccine safety, both in developing countries and in the United States,
are auto-disposable syringes and safety boxes, monodose prefilled in-
jection devices, needle-free injections, and thermostable vaccines that
The FDA has worked
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eliminate the need for refrigerated equipment and its associated main-
tenance.18  Table 1 highlights the impact of such technology change on
immunization services.
The Federal Government as Purchaser:
Vaccines for Children Program and Section 317 Grants
A number of federal funding streams provide assistance to the states
for vaccine purchases and immunization programs. While states use their
own funds (as well as in-kind support) to varying degrees, most rely
significantly on federal monies. Some states have virtually no state funds
devoted to vaccine purchase and depend almost entirely on federal mon-
ies. Grants are provided to the states, primarily through the Vaccines
for Children (VFC) program and Section 317 immunization categorical
TABLE 1
Impact of Technology Change on Immunization Services
Safer Multidose Vaccine
Delivery
Safe injection devices and
disposal technology assured
for mass immunization.
Lowest cost per delivered
multivalent dose of new
vaccine.
No reuse of syringes possible.
Reduced needle-stick risks.
Sterilization assured by
monitoring—or eliminated.
Progressive elimination of
complex and risky sterilization
procedures.
Progressive improvement in
waste management systems.
Higher cost for improved
safety.
Monodose Prefilled Injection
Devices
Ease of administration,
permitting community care
providers to immunize.
A single dose available to a
single child always.
No reuse of injection devices
possible.
Vaccine dose integrity and
sterility guaranteed to the
point of use.
No possibility of manual
manipulation of vaccine.
Elimination of administrative
vaccine wastage, resulting in
lower costs.
Reduced reliance on
refrigeration and ice-making
at the peripheral level, where
75% of distribution costs are
concentrated.
Less equipment maintenance.
Easier stock control.
Thermostable Vaccines
Delivered with Drugs
Vaccines carried to people
wherever they live, with no
refrigeration impediment.
Potency of vaccine assured for
every child, wherever he/she
lives.
Elimination of needle and
consequent elimination of
needle-stick hazard.
Reformed health systems able
to integrate drugs fully with
vaccines.
Complete elimination of
refrigeration in the distribution
system, leading to reduced
costs and managerial burden.
Easier stock control.
Aspect of
Services Impacted
Equity of Access to
New Vaccines
Safety of Vaccine
Administration
Simplicity and
Efficiency of
Vaccine Delivery
Technology Change
Source: J. Lloyd, Technologies for Vaccine Delivery in the 21st Century.
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grants. In its 2002 report Calling the Shots: Immunization Finance Policies
and Practices, the IOM noted that “in FY 1999, the federal government
supplied more than $600 million in (primarily childhood) vaccines to the
states through the Section 317 and [VFC] programs.”19
In an effort to improve vaccine availability nationwide, Congress cre-
ated the VFC program as part of the Omnibus Budget Reconciliation Act
of 1993. The program, which is funded through Medicaid and adminis-
tered by the CDC, provides publicly purchased vaccine, for eligible chil-
dren, at no charge to public and private health care providers in all
states and U.S. territories. To be eligible, children must fall into one of
the following four categories: Medicaid-eligible, uninsured, Native
American or Alaska Native origin, or underinsured (that is, covered by
insurance that does not cover vaccines). VFC will cover the immuniza-
tion in this last eligibility category only if it is received in a federally
qualified heath center or in a rural health center.20
Coordinating eligibility for children in Medicaid, the State Children’s
Health Insurance Program (SCHIP), and the VFC program has been a
thorny issue for the states. Most troublesome is the fact that children
previously eligible for VFC lose their eligibility if they are enrolled in a
non-Medicaid expansion SCHIP plan. In these cases, the state has to pay
the cost of the vaccine for those SCHIP children who are considered by
the state to be privately insured. The issue now is who pays for the
vaccine. This is frustrating for these states because, instead of being
purchased wholly with federal dollars, the vaccines are bought with a
combination of state and federal dollars. In addition to the associated
administrative headaches, the vaccines purchased under this arrange-
ment are more expensive because states do not typically purchase vac-
cines at the discounted federal price.
Section 317 of the Public Health Service Act provides for grants adminis-
tered by the CDC and awarded annually based on proposals submitted
by states and territories. These grants not only are used to purchase vac-
cines but also can be used to support immunization infrastructure im-
provements in such areas as outreach, data collection, and surveillance of
coverage levels and vaccine safety, as well as professional education. While
these grant monies increased significantly during the mid-1990s—rising
from a total of $37 million awarded for 1990 to $261 million for 1995—by
1999, the grants had declined to $111 million.21  Since then, however, the
funding has increased substantially. “Overall, state and local governments
are expected to receive $427 million in 2002 Section 317 funding, an in-
crease of 57 percent over levels received in 2000.” (See table on Section
317 support for state and local immunization, provided by Federal Funds
Information for States, appended to this document.)22
Further complicating state childhood vaccine fiscal matters is the fact that
the appropriations cycles of many states are out of sync with the Section
317 funding cycle. They can also be out of sync with recommendations of
Coordinating eligibility
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the CDC Advisory Committee on Immunization Practices. The result is
that states are vulnerable to unforeseen costs, such as those arising from
changes in childhood vaccine schedules or the introduction of new vac-
cines. For example, even though states can use Section 317 funding for
new as well as existing vaccines, when Prevnar, an important new pneu-
mococcal conjugate vaccine was introduced, many states choosing to
offer the vaccine were faced with a budgetary short-fall.
PUBLIC- AND PRIVATE-SECTOR COOPERATION:
PROVIDERS, REGISTRIES, AND EDUCATION
Providers in both the public and private sectors are the key to a success-
ful vaccine program. Until recently, immunization providers in the United
States had not been well defined. A February 2002 article published in the
American Journal of Public Health attempted to provide such a character-
ization, specifically seeking answers to the following questions: How many
practices and clinics provide vaccinations to children? How many chil-
dren are served in the public and the private sectors? What is the overall
capacity of the system to deliver vaccinations to the birth cohort? How
evenly is this capacity distributed? Relying upon 1997 data from the Na-
tional Immunization Survey23  and the VFC programs, the researchers
concluded that “U.S. childhood vaccination provider capacity is adequate.
Efforts to raise coverage rates should focus on increasing preventive care
use among children, improving the vaccination performance of provid-
ers, and ensuring continuity of care.”24
Traditionally, individual health care providers have been required to re-
port vaccine-related adverse events as well as disease outbreaks. Some
argue, however, that there is room for improvement and are calling for
greater private-sector assistance in monitoring patterns of vaccine cover-
age and disease outbreaks within a community. Bruce Gellin, M.D., ex-
ecutive director of the National Network for Immunization Information,
for example, has underscored the need for systematic tracking of vaccine
delivery. “There is a practical issue here. If the vaccine is not available
when you need it, someone needs to keep track and reschedule doctor
visits. The confusion and chaos is substantial.”25
Increasingly, states are relying upon registries to keep track of immuniza-
tions—identifying areas of need and monitoring adverse effects.26  For a
registry to be successful, however, it must have the support of parents
and the providers administering the vaccines. These systems must be
compatible with the operations of the private physician office and have
the backing of health professionals. Similarly, health officials stress that
parents need to recognize the value of having access to immunization
registries and have confidence that their child’s privacy will be protected.
Aware of the difficulties in reaching all children, some officials are calling
for the creation of a national educational campaign, designed to explain
the merits of childhood vaccine policy. Such a campaign, they stress, will
Increasingly, states
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need to address the broad constellation of concerns raised by parents
and others. The direct support and involvement of the private sector
are critical to its success.
Highlighting the success of one state’s efforts to improve immunization
rates, via registries and education campaigns, the National Conference of
State Legislature’s Kristine Goodwin gave the following example:
In Utah, which has one of the highest birth rates in the nation and a
history of ranking at the bottom of states in immunization levels, offi-
cials have had impressive success in boosting vaccination rates, dou-
bling the percentage of immunized two-year olds, from 37 percent in
1991 to 82 percent in 1999. Linda Abel, immunization program man-
ager in the Department of Health, said the state turned a corner in 1994,
when First Lady Jacalyn Leavitt championed an aggressive “Immu-
nize by Two: It’s Up To You” campaign. Since then, she said, there’s
been a “consistent message” and tenacity and coordination on the part
of public- and private-sector partners, including the state’s largest
HMO, the Utah PTA and corporations like McDonald’s, Wal-Mart and
Krogers. Accomplishments include: a statewide registry, a media pro-
motion, a home visiting program and a high profile “Care-A-Van” that
brings the campaign to local stores and schools. While the van dis-
penses vaccines, Abel said its more important contribution is “getting
the message out” about the value of immunizations.27
VACCINE MANUFACTURER CONCERNS AND
CHALLENGES
Beginning in the 1980s, with the rise in childhood vaccine safety lawsuits,
a number of companies dropped out of the vaccine market. The passage
of the NCVIA and the no-fault compensation it provided under the Na-
tional Vaccine Injury Compensation Program created what many believed
was a win-win situation for patients and companies, although parents
and providers remain concerned about the cumbersome process and low
payouts. Recently, a proliferation of class-action suits, the great majority
of which are related to thimerosal, has companies concerned.
Manufacturing and Production
As noted earlier, companies producing biologic agents such as vaccines
face significant manufacturing and production challenges.28  Because vac-
cines require the use of biologic organisms, each vaccine is unique in terms
of its manufacturing. In addition, production time is long, and purity
and potency tests are strict.
Commenting in a March 4, 2002, American Medical News cover story on
vaccine shortages, Wayne Pisano, an executive vice president at Aventis
Pasteur explained:
It takes Aventis Pasteur between 27 and 32 weeks to produce a purified
bulk lot of Td [tetanus and diphtheria] vaccine. Production is followed
Beginning in the 1980s,
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by eight to ten weeks of testing and four to six weeks of packaging and
final approvals. All in all, it takes about 11 months to produce a lot of
Td vaccine.29
Pisano went on to explain that additional manufacturing challenges have
involved the voluntary removal of the preservative thimerosal from all
childhood vaccines in order to address concerns that thimerosal poten-
tially posed health risks, since such concerns could lead to a decline in
the number of children being vaccinated. Aventis accomplished this by
repackaging its diphtheria, tetanus, and acellular pertussis (DtaP) from
multidose to single-dose vials to avoid the risk of contamination. This
process necessitated additional licensing work with the FDA. According
to Pisano, “the net effect is that we invested approximately two years’
development effort to replace an existing product.” Other experts note
that the time spent creating thimerosal-free vaccines (for existing prod-
ucts) had a direct impact on supply. That is, creating single-dose vials
decreased the yield of vaccine produced and thus contributed to the vac-
cine shortage.
Other production difficulties exist and, given the extremely limited num-
ber of vaccine manufacturers, even planned renovations to manufactur-
ing plants can disrupt supply. When Merck & Co., Inc., the nation’s only
MMR and chickenpox vaccine manufacturer experienced production
delays from a shutdown of its operations twice in two months, there
was no other company to step in and fill the gap.
Many of these circumstances have led manufacturers to withdraw from
the vaccine market, increasing the levels of shortages. Recent vaccine short-
ages began in November 2000 when supplies of the Td booster declined.
Then, in January 2001, Wyeth Pharmaceuticals, after 50 years of produc-
ing tetanus and diphtheria vaccines, announced plans to halt production.
That left only two companies, Aventis Pasteur and Glaxo SmithKline for
DtaP production and Aventis as the sole manufacturer of the Td booster.
Today, only four manufacturers produce vaccine for the nation’s children.
In addition to the manufacturing and production challenges, compa-
nies have expressed frustration in trying to pin down demand, which
often exceeds their projections. To some extent, it is a very expensive
guessing game—the price of which is measured not only in cost but
also in vaccine availability.
CHILDHOOD VACCINE SHORTAGES:
PROPOSED SOLUTIONS AND POLICY CHANGES
In the short term, recent vaccine shortages have caused the federal gov-
ernment temporarily to scale back recommendations regarding the tim-
ing of immunizations and to advise directing the available supply of vac-
cines to those children at higher risk of contracting vaccine-preventable
diseases. They have also led many states to suspend some immunization
13
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requirements related to day care and school attendance and ration the
amount of vaccines distributed to providers.30
For the long term, a number of possible solutions have been suggested
as health officials, manufacturers, and the government have sought to
resolve the complex issues that have contributed to the shortages and
to prevent their recurrence. Experts readily acknowledge that these
solutions have implications for the country’s emergency preparedness
capabilities.
In addition to their day-to-day vaccine-related responsibilities, several
federal committees and agencies function to address vaccine shortages,
as summarized in Table 2.
A number of steps have been taken in an effort to understand better the
dynamics of childhood vaccine availability and to prevent future short-
ages. Most recently, Congress requested that the General Accounting
Office (GAO) study the matter. The report, Childhood Vaccines: Ensuring
an Adequate Supply Poses Continuing Challenges, released in September
2002, made several recommendations to the DHHS secretary to help
TABLE 2
Federal Agency and Committee Functions
Related to Averting or Mitigating Vaccine Shortages
Agency/Committee
Advisory Committee on
Immunization Practices
(ACIP)
Centers for Disease
Control and Prevention
(CDC)
Food and Drug
Administration
(FDA)
National Vaccine
Program Office
(NVPO)
National Vaccine
Advisory Committee
(NVAC)
Function
Evaluate and recommend changes in the immunization
schedule to accommodate reduced supplies.
Monitor production, monitor inventories of state
immunization programs, manage distribution of public
supplies, administer stockpiles, track back orders, and
work with ACIP to modify immunization schedules in
order to respond to vaccine shortages.
Accelerate review of revisions to existing licenses and
vaccine lots submitted for release. Work with
manufacturers to correct violations of good
manufacturing practices that could disrupt production.
Facilitate development of contingency plans, identify
the reasons for shortages and options to address them,
and identify strategies to prevent future shortages.
Study and make recommendations to the DHHS
assistant secretary for health on ways to achieve an
adequate supply of safe and effective vaccines.
Source: U.S. General Acounting Office, Childhood Vaccines: Ensuring an Adequate Supply Poses
Continuing Challenges (GAO-02-987), September 2002.
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promote the availability of vaccine products. These included “adding
vaccines to the types of products that can be considered under FDA’s
authority to expedite the approval of products in development trials
and directing CDC to address several operational and strategic issues
in expanding childhood vaccine stockpiles.”31
In February 2002, the DHHS National Vaccine Advisory Committee con-
vened a group consisting of vaccine companies, physicians, insurers, and
federal agency personnel to articulate the problems and develop solu-
tions. Among the group’s recommendations were the following:
■ Stabilize the supply by creating additional stockpiles of vaccines that
could be used during shortages.
■ Increase liability protection for manufacturers and physicians.
■ Streamline the regulatory process.
■ Require manufacturers to provide adequate notice before they
voluntarily stop production.
■ Create a national education outreach and advertising campaign on
the importance and real value of vaccines.
Sen. Bill Frist (R-Tenn.), along with cosponsors Sens. Kay Bailey Hutchison
(R-Tex.), Jim Bunning (R-Ky.), Zell Miller (D-Ga.), Jim Jeffords (I-Vt.) and
Gordon Smith (R-Ore.) have introduced legislation, S. 2053, the “Improved
Vaccine Affordability and Availability Act,” which would require the fed-
eral government to establish and maintain a six-month stockpile of pri-
oritized (childhood and adult) vaccines. In addition, the legislation would
expand the funding available for state and local efforts to raise immuni-
zation rates among adults and children who are underserved or at a high
risk for vaccine-preventable diseases. Lastly, the bill would “restore bal-
ance” to the National Vaccine Injury Compensation Program.32  Other
provisions of the bill would ensure that claimants, including third par-
ties, file timely claims through the vaccine injury compensation process
before suing in court and ensure predictability for manufacturers by clari-
fying that ingredients in the FDA-approved vaccine may not be consid-
ered to be adulterants or contaminants in that vaccine.
In addition to the recommended solutions listed above, other experts have
suggested providing additional market incentives, including tax incen-
tives for manufacturers. Pediatricians are calling for increased reimburse-
ment, urging the Centers for Medicare and Medicaid Services to recog-
nize the physician work associated with administering vaccines. “It would
be unreasonable to expect that pediatricians can afford to continue to
administer vaccines if the costs to the practice are more than the reim-
bursement.”33  Increasing FDA funding in the area of vaccine testing re-
search has also been suggested as a necessary step toward strengthening
childhood vaccine supplies.
Others, including the Institute of Medicine, have called for a National
Vaccine Authority to carry out a number of functions, such as defining
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the need and assessing the market for vaccines, helping establish and
oversee a government-owned factory, spurring private vaccine devel-
opment by guaranteeing prices for immunizations, financing vaccine re-
search, and assisting companies in the production of pilot vaccine lots.
There appears to be little agreement at this point, however, that a new
federal entity is the answer. Critics of this approach point out, for ex-
ample, that any government-owned or operated vaccine facility would
experience the same good manufacturing practice challenges and liabil-
ity challenges that private companies face.
Despite some differences of opinion over some of the recommendations,
there is overwhelming agreement that forging stronger public-private
partnerships is critical. It is generally recognized and acknowledged that
the challenges are too broad for either the private or the public sector to
tackle alone. The costs and risks associated with vaccine research, devel-
opment, and manufacturing are, according to most experts, too high for
the private sector to shoulder alone. Similarly, most agree that the patch-
work system of federal and state vaccine programs creates confusion and
obfuscates the roles and responsibilities of all parties.
The unpredictability of demand and the fluctuations in federal financing
urgently point to the need for what the IOM’s Calling the Shots referred to
as a “national strategic vision,” one that calls for a strengthening of the
federal and state immunization partnership. The IOM identified six fun-
damental roles for such a system: “to assure the purchase of vaccines, to
assure service delivery, to prevent and control infectious disease, to moni-
tor and survey levels of immunization coverage and vaccine safety con-
cern, especially within high-risk settings, to sustain and improve vaccine
coverage rates for child and adult populations, and to use primary care
and public health resources efficiently in achieving national immuniza-
tion goals.”
According to the IOM and other experts, long-term vaccine supply and
safety issues can be resolved only by a robust public-private partnership
and an enhanced public health infrastructure. Ultimately, the answer to the
question of what the government’s role in ensuring an adequate childhood
vaccine supply should be must be answered in a way that addresses both
today’s shortages and tomorrow’s as-yet-unknown shortages and risks.
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Glossary*
Acellular vaccine — A vaccine containing partial cellular material as
opposed to complete cells.
Active immunity — The production of antibodies against a specific dis-
ease by the immune system. Active immunity can be acquired in two
ways, either by contracting the disease or through vaccination. Active
immunity is usually permanent, meaning individuals are protected from
the disease for the duration of their lives.
Adjuvant — A substance (for example, aluminum salt) that is added
during production to increase the body’s immune response to a vaccine.
Adverse events — Undesirable experiences occurring after immuniza-
tion that may or may not be related to the vaccine.
Advisory Committee on Immunization Practices (ACIP) — A panel of
15 experts who make recommendations on the use of vaccines in the
United States. The panel is advised on current issues by representatives
from the Centers for Disease Control and Prevention, Food and Drug
Administration, National Institutes of Health, American Academy of
Pediatrics, American Academy of Family Physicians, American Medical
Association, and others. The recommendations of the ACIP guide im-
munization practice at the federal, state, and local level.
Attenuated vaccine — A vaccine in which live virus is weakened through
chemical or physical processes in order to produce an immune response
without causing the severe effects of the disease. Attenuated vaccines
currently licensed in the United States include measles, mumps, rubella,
polio, yellow fever, and varicella. Also known as live vaccine.
Booster shots — Additional doses of a vaccine needed periodically to
“boost” the immune system. For example, the tetanus and diphtheria
(Td) vaccine which is recommended for adults every ten years.
Brachial neuritis — Development of a disease despite a person’s having
responded to a vaccine.
Combination vaccine — Two or more vaccines administered at once in
order to reduce the number of shots given. For example, the MMR
(measles, mumps, rubella) vaccine.
Community immunity — Having a large percentage of the population
vaccinated in order to prevent the spread of certain infectious diseases.
Even individuals not vaccinated (such as newborns and those with chronic
illnesses) are offered some protection because the disease has little op-
portunity to spread within the community. Also known as herd immunity.
Conjugate vaccine — The joining together of two compounds (usually
a protein and polysaccharide) to increase a vaccine’s effectiveness.
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Epidemic — The occurrence of disease within a specific geographical
area or population that is in excess of what is normally expected.
Etiology — The cause of.
Herd immunity — See community immunity.
Immune system — The complex system in the body responsible for
fighting disease. Its primary function is to identify foreign substances in
the body (bacteria, viruses, fungi or parasites) and develop a defense
against them. This defense is known as the immune response. It in-
volves production of protein molecules called antibodies to eliminate
foreign organisms that invade the body.
Immunity — Protection against a disease. There are two types of immu-
nity, passive and active. Immunity is indicated by the presence of anti-
bodies in the blood and can usually be determined with a laboratory
test. See active immunity and passive immunity.
Immunization — The process by which a person or animal becomes
protected against a disease. This term is often used interchangeably
with vaccination or inoculation.
Inactive vaccine — A vaccine made from viruses and bacteria that have
been killed through physical or chemical processes. These killed organ-
isms cannot cause disease.
Incubation period — The time from contact with the infectious agents
(bacteria or viruses) to onset of disease.
Infectious agents — Organisms capable of spreading disease (for ex-
ample, bacteria or viruses).
Investigational vaccine — A vaccine that has been approved by the
Food and Drug Administration (FDA) for use in clinical trials on hu-
mans. However, investigational vaccines are still in the testing and evalu-
ation phase and are not licensed for use in the general public.
Live vaccine — See attenuated vaccine.
Microbes — Tiny organisms (including viruses and bacteria) that can
be seen only with a microscope.
Outbreak — Sudden appearance of a disease in a specific geographic
area (such as a neighborhood or community) or population (for example,
adolescents).
Pandemic — An epidemic occurring over a very large area.
Passive immunity — Protection against disease through antibodies pro-
duced by another human being or animal. Passive immunity is effective,
but protection is generally limited and diminishes over time (usually a
few weeks or months). For example, the maternal antibodies are passed
to the infant prior to birth. These antibodies temporarily protect the
baby for the first 4 to 6 months of life.
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Pathogens — Organisms (for example, bacteria, viruses, parasites, and
fungi) that cause disease in human beings.
Prevalence — The number of disease cases (new and existing) within a
population over a given time period.
Quarantine — The isolation of a person or animal who has or is sus-
pected of having a disease, in order to prevent further spread of the
disease.
Smallpox — An acute, highly infectious, often fatal disease caused by a
poxvirus and characterized by high fever and aches with subsequent
widespread eruption of pimples that blister, produce pus, and form pock
marks, also called varioles.
Strain — A specific version of an organism. Many diseases, including
HIV/AIDS and hepatitis, have multiple strains.
Vaccination — Injection of a killed or weakened infectious organism in
order to prevent the disease.
Vaccine — A product that produces immunity, therefore protecting the
body from the disease. Vaccines are administered through needle injec-
tions, by mouth, and by aerosol.
Vaccine Adverse Event Reporting System (VAERS) — A database man-
aged by the Centers for Disease Control and Prevention and the Food
and Drug Administration. VAERS provides a mechanism for the collec-
tion and analysis of adverse events associated with vaccines currently
licensed in the United States. Reports to VAERS can be made by the
vaccine manufacturer, recipient, recipient’s parent/guardian, or health
care provider. For more information on VAERS call (800) 822-7967.
Vaccine Safety Datalink Project (VSD) — In order to increase knowl-
edge about vaccine adverse events, the Centers for Disease Control and
Prevention have formed partnerships with eight large health mainte-
nance organizations (HMOs) to continually evaluate vaccine safety. The
project contains data on more than 6 million people. Medical records are
monitored for potential adverse events following immunization. The
VSD project allows for planned vaccine safety studies as well as timely
investigations of a hypothesis.
Waning immunity — The loss of protective antibodies over time.
*Adapted from “Glossary,” National Immunization Program, Centers for Disease Control and
Prevention, http://www.cdc.gov/nip/webuti/terms/glossary.htm.
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Table 1 
 Section 317 Support for State and Local Immunization 
(calendar years; dollars in thousands)  
Vaccine 2000
Operations Vaccines Total Share Awards Amount Percent
Alabama $3,621 $3,129 $6,750 46% $4,045 $2,705 67%
Alaska 2,198 2,022 4,220 48% 2,576 1,644 64%
Arizona 3,687 3,865 7,552 51% 4,086 3,466 85%
Arkansas 2,148 3,561 5,709 62% 3,334 2,375 71%
California 23,373 11,314 34,687 33% 24,627 10,060 41%
Colorado 2,978 3,891 6,870 57% 3,094 3,776 122%
Connecticut 2,742 2,653 5,394 49% 5,056 338 7%
Delaware 1,073 292 1,365 21% 608 757 124%
District of Columbia 1,502 1,363 2,865 48% 1,227 1,638 134%
Florida 8,623 5,424 14,047 39% 5,606 8,441 151%
Georgia 5,314 2,184 7,497 29% 3,423 4,074 119%
Hawaii 1,696 1,583 3,279 48% 1,376 1,903 138%
Idaho 1,525 2,213 3,738 59% 2,152 1,586 74%
Illinois 8,709 12,213 20,922 58% 11,455 9,467 83%
Indiana 3,694 6,644 10,338 64% 4,707 5,631 120%
Iowa 1,789 2,526 4,316 59% 2,718 1,598 59%
Kansas 1,825 2,821 4,647 61% 2,820 1,827 65%
Kentucky 2,447 1,692 4,138 41% 3,423 715 21%
Lousiana 2,130 5,197 7,327 71% 4,306 3,021 70%
Maine 1,962 2,687 4,649 58% 2,374 2,275 96%
Maryland 4,125 2,987 7,113 42% 5,452 1,661 30%
Massachusetts 6,368 6,750 13,118 51% 18,014 -4,896 -27%
Michigan 6,447 11,205 17,652 63% 17,131 521 3%
Minnesota 3,204 2,747 5,952 46% 4,658 1,294 28%
Mississippi 2,697 2,169 4,866 45% 4,500 366 8%
Missouri 3,619 4,036 7,655 53% 6,092 1,563 26%
Montana 543 736 1,279 58% 896 383 43%
Nebraska 1,627 1,370 2,996 46% 1,812 1,184 65%
Nevada 1,849 2,608 4,456 59% 4,715 -259 -5%
New Hampshire 1,772 1,375 3,146 44% 2,624 522 20%
New Jersey 4,324 4,655 8,979 52% 5,221 3,758 72%
New Mexico 1,715 1,687 3,402 50% 1,798 1,604 89%
New York State 15,986 8,020 24,006 33% 12,771 11,235 88%
North Carolina 5,234 8,669 13,902 62% 7,251 6,651 92%
North Dakota 772 1,307 2,080 63% 1,566 514 33%
Ohio 6,347 12,330 18,678 66% 6,744 11,934 177%
Oklahoma 3,424 4,804 8,228 58% 3,981 4,247 107%
Oregon 2,597 2,103 4,699 45% 2,972 1,727 58%
Pennsylvania 7,336 4,226 11,562 37% 6,692 4,870 73%
Rhode Island 1,603 1,239 2,842 44% 1,883 959 51%
South Carolina 3,022 5,012 8,034 62% 3,275 4,759 145%
South Dakota 776 1,782 2,558 70% 1,474 1,084 74%
Tennessee 2,744 6,152 8,896 69% 5,914 2,982 50%
Texas 15,246 21,281 36,527 58% 22,342 14,185 63%
Utah 2,259 2,275 4,534 50% 1,325 3,209 242%
Vermont 1,216 1,080 2,296 47% 1,484 812 55%
Virginia 4,166 2,795 6,961 40% 5,619 1,342 24%
Washington 4,081 4,846 8,927 54% 5,714 3,213 56%
West Virginia 1,989 921 2,911 32% 1,941 970 50%
Wisconsin 4,280 2,585 6,865 38% 4,703 2,162 46%
Wyoming 867 1,112 1,979 56% 969 1,010 104%
Puerto Rico 3,225 1,961 5,185 38% 5,732 -547 -10%
Virgin Islands 752 39 791 5% 480 311 65%
Pacific Territories 1,135 2,321 3,456 67% 1,763 1,693 96%
TOTAL $210,385 $216,454 $426,839 51% $272,520 $154,319 57%
Note:  For Illinois, New York, Pennsylvania and Texas, includes awards directly to selected cities.
Source:  CDC administrative tables.
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